Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Merola JF., Landewé R., McInnes IB., Mease PJ., Ritchlin CT., Tanaka Y., Asahina A., Behrens F., Gladman DD., Gossec L., Gottlieb AB., Thaçi D., Warren RB., Ink B., Assudani D., Bajracharya R., Shende V., Coarse J., COATES LC.